Overview of Fluad

What is Fluad? Defining its Pharmaceutical Class and Form

Property	Description
Active ingredient	Influenza virus surface antigens
Form	Suspension for injection (Injectable Emulsion)
Pharmacological class	Viral Vaccine, Active Immunizing Agent
Common use	Active protection against seasonal influenza
Origin	Biologic product (derived from inactivated viral components)

Fluad is an Adjuvanted Inactivated Influenza Vaccine (aIIV), which belongs to the pharmacological class of Viral Vaccines or Active Immunizing Agents. It is prepared as a sterile injectable emulsion—a milky-white suspension for injection—designed for intramuscular (IM) injection. Fluad is specifically indicated for use in adults 65 years of age and older, a population for whom adjuvanted influenza vaccines are used to provide enhanced immune protection.

Composition and the Role of Surface Antigens and MF59

The core of Fluad is its combination product composition, containing inactivated influenza virus surface antigens—specifically Haemagglutinin and Neuraminidase—from seasonal A and B strains. Its most distinctive feature is the inclusion of the MF59 adjuvant, an oil-in-water emulsion containing squalene. This component distinguishes Fluad from non-adjuvanted alternatives and is included to boost the immune response. As a biologic product derived from viral components, this mechanism is designed to stimulate immunity in the target patient group.

The General Purpose of Fluad: Active Protection against Seasonal Influenza

The overall purpose of Fluad is to provide active protection and immunization against illness caused by seasonal influenza disease. This formulation is designed to help the body generate a stronger humoral antibody response compared to standard-dose, non-adjuvanted vaccines. This focus on Immune Enhancement is intended to provide defense against circulating virus strains, serving as a public health tool for older individuals who face higher risks from influenza complications.

What side effects are possible with Fluad?

Possible Side Effects and Safety Information

The safety profile of Fluad, an Adjuvanted Inactivated Influenza Vaccine, is formally classified in regulatory documents based on the frequency and the affected system-organ class, with data primarily derived from the target population of adults 65 years of age and older.

Documented Adverse Reactions

The most commonly documented adverse reactions are categorized as Very Common (occurring in ge 1 in 10 individuals) and involve localized injection site reactions and general systemic effects.

Classification	Affected Systems and Reactions	Time Pattern
Very Common	Injection site pain/tenderness, Myalgia (muscle pain), Fatigue, Headache	Onset within 2 days, typically resolves within 3 days
Common	Injection site redness (erythema), Induration, Ecchymosis (bruising), Diarrhea, Nausea, Fever, Shivering	Onset within 2 days, typically resolves within 3 days

Less frequent adverse effects classified as Uncommon include vomiting and lymphadenopathy. Regulatory data also list various effects under specific System-Organ Classes, including Nervous System disorders, Musculoskeletal disorders, and Gastrointestinal disorders, reflecting the comprehensive surveillance approach.

Serious Adverse Events and Safety Considerations

Adverse reactions reported in post-marketing surveillance, where frequency is generally classified as Not Known, include rare, clinically significant events such as Anaphylaxis (severe allergic reaction), Guillain-Barré Syndrome (GBS), and certain cases of Vasculitis and Thrombocytopenia.

Population-specific safety notes are included in official labeling. For example, individuals who are immunocompromised may experience a lower immune response. Caution is also noted for persons with bleeding disorders due to the risk of bleeding following the required intramuscular administration. Furthermore, the label notes the potential for Syncope (fainting) as a psychogenic response to the administration process itself.

Overdose and Emergency Response

Overdose and when to seek help

The regulatory information concerning overdosage of Fluad focuses on the expected outcome of administering a dose exceeding the recommended amount. As an adjuvanted inactivated vaccine, the official prescribing information from regulatory authorities does not list specific clinical signs or symptom clusters that constitute an overdose presentation in the manner of other systemic pharmacological agents.

The core regulatory assessment is that an overdosage is unlikely to have any untoward effect. This determination establishes that a specific toxicological profile, including severe or life-threatening outcomes, is not anticipated from an accidental over-administration. Consequently, the official documentation does not contain mandatory help-seeking instructions specific to overdose, nor does it define specific procedural steps or monitoring requirements, such as hospital observation or the use of an antidote.

Official Overdose Status

Category	Regulatory Assessment (Official Label)
Documented Manifestations	Untoward effects are considered unlikely.
Emergency Actions	No specific mandatory actions are documented for overdosage.
Supportive Management	No specific antidote or supportive treatment is defined.

This official status reflects the regulatory position that the risk of specific, adverse effects stemming directly from an over-dose exposure is low. Therefore, the regulatory basis establishes that specific criteria for seeking urgent medical help solely due to an excessive dosage are not detailed in the official prescribing information.

Therapeutic Uses of Fluad

Fluad is applied for active immunization to help prevent seasonal influenza disease caused by the specific virus subtypes contained in the annual formulation. It is commonly used for persons 65 years of age and older, a population for whom it is relevant in clinical settings where an enhanced immune response is a therapeutic goal.

Focus on Severe Outcomes and Complications

The primary therapeutic focus is relevant for managing the risk associated with severe illness and serious complications related to the flu infection. Its use in the geriatric population may assist with managing the risk of influenza-related hospitalization and the development of pneumonia, which can create noticeable physiological strain. It helps address symptom clusters that may become intense or disruptive and contributes to easing the overall symptom burden for patients at higher risk, including those with underlying chronic medical conditions like cardiovascular disease or diabetes.

Quick Fact: Prevention of Systemic Ailments (Fluad is applied to help prevent the onset of symptoms related to systemic imbalance, including severe fever and debilitating fatigue).

Eligibility and Restrictions for Use

The eligibility for receiving Fluad is strictly defined by regulatory authorities based on age, hypersensitivity history, and clinical status.

Eligibility Scope

Category	Official Regulatory Status
Approved Age Group (US)	Adults 65 years of age and older
Populations Contraindicated	Anyone with a history of severe allergic reaction (e.g., anaphylaxis) to any component of the vaccine, including egg protein, or to a previous influenza vaccine
Age-Related Limitations	Not approved for use in persons under 65 years of age (US label); safety and efficacy not established in children under 18 years
Pregnancy and Lactation Status	Not indicated for use in pregnant women; not to be used in women who are breast-feeding

Eligibility-Related Restrictions

Acute Febrile Illness: Vaccination should be postponed until the fever is resolved.
Guillain-Barré Syndrome (GBS): A history of GBS within six weeks of a previous influenza vaccination necessitates a careful consideration of the potential benefits and risks before administration.

The regulatory documents exclusively define the use of Fluad by concentrating its indication on the older-adult population. Non-eligibility is established through absolute contraindications concerning severe allergic history. Other uses, such as in younger age groups or during pregnancy and lactation, are officially noted as being not established or not recommended by regulatory agencies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory interaction profile for Fluad is defined by its status as an active immunizing agent, focusing on pharmacodynamic effects and administration requirements.

Interaction Scope

Category	Official Regulatory Statement
Medicinal product categories with documented interactions:	Immunosuppressive therapies, including corticosteroid therapies
Specific interacting medicines (if explicitly listed):	Other Vaccines, relevant for co-administration procedures.
Mechanistic basis of interactions (only if stated in label):	Pharmacodynamic interference, resulting in a documented reduced immune response. No pharmacokinetic interactions (CYP enzymes or transporters) are formally documented.
Timing-based interaction rules (if applicable):	If co-administered with other vaccines, Fluad must be administered at separate injection sites and preferably on different limbs.
Population-specific interaction notes (if applicable):	The interaction leading to a diminished antibody response is specifically noted for immunocompromised persons receiving concurrent immunosuppressive therapy.
Interaction-related restrictions:	Fluad must not be mixed with any other vaccines in the same syringe. No drug-drug combination is formally classified as contraindicated.

Resulting Interaction Structure

The profile officially documents a pharmacodynamic interference resulting in a diminished immune response when the vaccine is used concurrently with immunosuppressive therapies. The interaction information is further structured by procedural constraints that mandate specific administration site separation when the vaccine is given simultaneously with other vaccines. No formal statements regarding interactions with food, alcohol, herbal products, or supplements are present in the official regulatory interaction sections.

Mechanism of Action

Initiation of Antigen-Specific Humoral Response

Fluad functions as an inactivated vaccine by presenting specific viral surface proteins—hemagglutinin and neuraminidase—from two influenza A subtypes and two influenza B types. This process engages immune mechanisms that lead to the production of antibodies targeted specifically against these antigens. This is the key mechanistic step in initiating the adaptive immune system.

Adjuvant-Mediated Pathway Modulation

The vaccine contains the MF59 adjuvant, an oil-in-water emulsion of squalene that is designed to modulate the immune response. This component recruits immune cells to the injection site and modifies early molecular steps, thereby inducing B-cell and T-cell activation. This engagement of mechanisms influences feedback regulation within pathways by promoting the localized presence of immune cells.

Antigen-Antibody Interaction

The development of anti-viral antibodies and a cellular response is a direct consequence of the vaccine's mechanism. Upon subsequent exposure to the actual influenza virus, these antibodies bind to the virus's surface proteins, preventing its attachment to and subsequent invasion of host cells. This molecular blockade constitutes the mechanism of action.

Dosage and Administration Information

Administration Overview

Fluad is an injectable vaccine administered by a healthcare professional. It is typically given as a single dose during the annual flu vaccination season. The vaccine is intended for intramuscular injection, with the preferred site usually being the deltoid muscle of the upper arm.

Preparation and Handling

Before administration, the vaccine is inspected visually for particulate matter and discoloration. The syringe is shaken gently to ensure the contents are well mixed. The vaccine should be at room temperature before it is injected.

Standard Procedure

The injection site is cleansed with an antiseptic.
The healthcare provider administers the vaccine using a sterile needle.
A small bandage may be applied to the injection site afterward.

Scheduling

Vaccination timing is generally determined by local seasonal patterns of influenza activity. Because the influenza virus changes frequently and the protection provided by the vaccine diminishes over time, annual administration is necessary to maintain protection against the strains predicted to circulate each year.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Fluad (aIIV)

This section provides an overview of the types of official research that has been conducted for Fluad, describing what studies have examined and the general patterns observed, while noting areas where more information is still needed.

1. Evidence for Immunogenicity and Protection Against Seasonal Influenza

Research was studied for its potential association with the body's immune response (known as immunogenicity). These studies primarily include Randomized Controlled Trials (RCTs). The research examined outcomes related to the production of antibodies and the rate at which individuals achieved a measured protective antibody level.

Observational studies were also applied to see the patterns of outcomes against laboratory-confirmed influenza illness across an entire flu season. The research primarily included adults 65 years of age and older.

Studies reported measurements of antibody levels that were observed to be higher for some strains and comparable for others when Fluad was evaluated against a standard, non-adjuvanted vaccine. These findings describe patterns observed in the studies, though antibody levels are considered a surrogate endpoint (an indirect measure) that requires supportive data to confirm clinical outcomes. Research is ongoing to further evaluate clinical outcomes.

2. Research on Severe Outcomes and Influenza-Related Complications

Beyond measuring the immune response, other research was studied for outcomes related to systemic or functional imbalance. These studies usually take the form of large-scale Observational Studies that analyze health databases across multiple flu seasons.

These large-scale studies research examined rates of hospitalization for influenza-related causes, including the development of pneumonia, in cohorts of older adults. Studies observed patterns related to hospitalization rates for influenza-related causes in cohorts who received Fluad compared to those who received a standard non-adjuvanted vaccine or no vaccine.

5. Evidence Consistency and Areas of Research Uncertainty

The evidence quality varies across studies. A key limitation is the reliance on surrogate endpoints for initial approval. The long-term effects are not fully established, and comparative evidence is lacking for some of the other enhanced flu vaccines available to older adults. Ultimately, research is ongoing to further characterize the patterns of immune response and clinical outcomes.

Frequently Asked Questions (FAQ)

Common questions about Fluad (FAQ)

Q: How long after receiving Fluad does it take to develop protection?

According to official product information, the body generally takes about 2 to 3 weeks after receiving the injection to develop protective levels of antibodies against influenza. Immunization occurs over this period.

Q: What is the difference between high-dose flu shots and adjuvanted shots like Fluad?

The two types of enhanced vaccines for older adults use different mechanisms. High-dose vaccines contain four times the amount of antigen (the active ingredient), while adjuvanted vaccines like Fluad contain the standard antigen dose but include the MF59 adjuvant to boost the immune response. Both types are available options intended to provide enhanced immune response in the target population.

Q: Is Fluad manufactured using egg-based or cell-based technology?

Fluad is an inactivated influenza vaccine. While the product label does not explicitly name the manufacturing platform, its composition and contraindications, which list egg and chicken proteins, point toward an egg-based process.

Q: Is it true that Fluad contains no thimerosal?

Yes, official product information confirms that Fluad is provided in a single-dose syringe and does not contain thimerosal. Thimerosal is a common mercury-containing preservative sometimes used in multi-dose vaccine vials.

Q: What are the different virus strains included in the quadrivalent version of Fluad?

Fluad Quadrivalent contains surface antigens from four influenza virus strains. These four strains include two influenza A subtypes (typically A(H1N1) and A(H3N2)) and two influenza B types, which are selected annually based on the World Health Organization's (WHO) recommendations for the seasonal period.

Q: What is the difference between Fluad Quadrivalent and the previous Trivalent formulation?

The current Quadrivalent formulation, sometimes known as Fluad Tetra, protects against four influenza virus strains (two A and two B). The previous Trivalent formulation was designed to protect against three strains (two A and one B). The Quadrivalent formulation was developed to include an additional B virus lineage for broader protection.

Q: Has Fluad been used widely in other countries outside the one where it is received?

Official data indicates that Fluad is approved in more than 30 countries worldwide. The vaccine has a history of widespread use, with hundreds of millions of doses distributed globally.

Q: What are the trace components found in Fluad that people might be concerned about?

Trace materials found in the vaccine are residuals from the manufacturing process. These potentially include antibiotics (such as kanamycin and neomycin sulphate), hydrocortisone, formaldehyde, and cetyltrimethylammonium bromide (CTAB).

Q: What ingredients in Fluad, besides egg protein, might cause an allergic reaction?

The vaccine is contraindicated for severe allergic reaction to any of its components. These components may include the active viral substances and trace processing materials such as formaldehyde, chicken proteins, and certain antibiotics like kanamycin and neomycin sulphate.

Q: Can Fluad be administered to a person who has a known egg allergy?

The official guidance states that the vaccine is contraindicated for anyone with a history of a severe allergic reaction to any of its components. Regulatory guidelines require that individuals with a history of anaphylaxis (a severe allergic reaction) to egg protein must receive the vaccine in a medical facility equipped and staffed for immediate management of anaphylaxis.

Q: What signs of an allergic reaction to Fluad would require immediate medical attention?

Immediate medical attention is required for signs of a severe allergic reaction, known as anaphylaxis. These signs include sudden onset of hives, rash, or itching, as well as swelling of the face, lips, tongue, or difficulty breathing.

Q: Can a person with a latex allergy safely receive Fluad?

Caution is noted for individuals with a latex allergy, as the official US product label indicates the tip caps of the pre-filled syringes may contain natural rubber latex. This component has the potential to cause allergic reactions in highly latex-sensitive individuals.

Q: Are injection site reactions like swelling and pain more common with Fluad than with other flu shots?

Official documents report injection site pain and swelling as common side effects that are usually mild and resolve quickly. While these common reactions are expected, rare but serious adverse events, such as severe, extensive limb swelling, have been reported in post-marketing surveillance.

Q: Is a fever after Fluad common, and what temperature is considered high?

Official sources classify fever as an uncommon side effect, meaning it occurs in fewer than 1 in 10 individuals. The product information lists a high temperature, such as a fever greater than 40 C (104 F), as a serious side effect that requires immediate medical attention.

Q: Are neurological symptoms like tingling or weakness ever reported after Fluad?

Reports from post-marketing surveillance have included neurological symptoms under nervous system disorders. These reported events have included paresthesia (a tingling or prickling sensation), muscular weakness, neuritis, neuralgia, and, rarely, Guillain-Barré Syndrome (GBS).

Q: What are the potential effects of Fluad on the ability to drive or use machinery?

According to the official product information, Fluad should not generally interfere with the ability to drive or operate machinery. However, temporary side effects such as dizziness, light-headedness, or tiredness have been reported in some individuals.

Q: Does Fluad contain any preservative?

Fluad is provided in a single-dose syringe and generally contains no preservatives. Official information confirms that it specifically does not contain thimerosal, which is a common mercury-containing preservative sometimes used in multi-dose vaccine vials.

Q: Does having an autoimmune condition affect the response to the Fluad vaccine?

Official product information notes that antibody responses generated by the vaccine may not be fully protective in all recipients, particularly in immunocompromised patients. This regulatory caution relates to conditions or treatments that suppress the immune system.

Q: Is it possible to receive Fluad if I am currently taking immune checkpoint inhibitors for cancer?

Regulatory labels note a potentially diminished immune response in persons receiving immunosuppressive therapies. Although this caution applies, available research has informed clinical guidance regarding the use of inactivated flu vaccination for patients receiving immune checkpoint inhibitors (ICIs).

Q: How should the timing of Fluad and other vaccines like the COVID-19 vaccine be managed?

The official product information does not specifically address the timing or interval needed between Fluad and other vaccines, such as the COVID-19 vaccine, if they are not given at the same time. If co-administered, regulatory guidance mandates that Fluad must be administered at a separate injection site from the other vaccine.

Q: Is Fluad available for individuals under the age of 65 in some regions or circumstances?

Fluad is officially approved for use in adults aged 65 years and older. However, current recommendations in some health jurisdictions allow the use of adjuvanted inactivated flu vaccine as an acceptable option for high-risk individuals aged 18–64, such as solid organ transplant recipients receiving immunosuppressive therapy.

Q: What type of medical professionals are authorized to administer the Fluad vaccine?

Fluad is typically administered as an intramuscular injection by a qualified healthcare professional. Depending on the local jurisdiction, this may include a doctor, nurse, or pharmacist, according to national protocols.

Q: How does the manufacturing process of Fluad ensure the virus is inactivated?

The viral components in Fluad are chemically inactivated to prevent the vaccine from causing influenza illness. This inactivation process in flu vaccine manufacturing is commonly performed using chemical agents such as formaldehyde.

Q: What is Oculorespiratory Syndrome (ORS) and is it linked to Fluad?

The condition known as Oculorespiratory Syndrome (ORS), which is characterized by a collection of eye and respiratory symptoms, is not listed as a specific documented adverse reaction in the official product information for Fluad.

How should Fluad be stored and disposed of?

How to Store and Dispose of Fluad?

Fluad is an injectable emulsion that requires strict adherence to cold chain requirements to maintain the integrity of its components. The official storage and disposal rules for the pre-filled syringe are defined by regulatory authorities.

Storage Requirements

Condition	Requirement	Restriction
Temperature	Store refrigerated between 2 C and 8 C (36 F and 46 F).	DO NOT FREEZE. The product must be discarded if it has been frozen.
Protection	Keep the pre-filled syringe in the original carton prior to use.	Protect from light.
Safety	Keep out of the sight and reach of children.

Disposal Requirements

As a single-dose preparation, any unused portion or expired product must be disposed of in accordance with local requirements for pharmaceutical waste. The medicine must not be discarded into wastewater or standard household trash unless explicitly permitted by local regulations.

Fluad